Rhythm AI, Ltd. appears in FDA 510(k) records as the legal applicant for the STAR Apollo™ Mapping System, filed under product code DQK and regulation 21 CFR 870.1425, Programmable Diagnostic Computer, Class II. The supplied collection contains one linked record, a 510(k) with a substantially equivalent decision, and the record sample lists that single filing. The company's own materials describe STAR Apollo as software for electrophysiologists that identifies sources of atrial fibrillation activation, and state that it is FDA cleared for use with two named mapping systems and not commercially available outside the U.S. [1][2][3]
Documented filings and their scope
The record sample lists K263380 for the STAR Apollo™ Mapping System, received September 24, 2026 and decided October 23, 2026 with decision code SESE, meaning substantially equivalent, under the cardiovascular advisory committee. The filing names Rhythm AI, Ltd. as applicant with a London address and product code DQK. The collection's decision counts show one SESE decision across the full set, and the sample decision counts show the same single decision for the one-record sample. [1]
An earlier clearance letter in the sources covers K253733, dated December 19, 2025, for the STAR Apollo™ Mapping System under the same regulation, class and product code, addressed to Rhythm AI, Ltd. at One London Wall, London. A 2022 determination letter covers K220786 for the same trade name, also under 21 CFR 870.1425 and product code DQK. These are separate filings from the record sample and are described here only as dated examples. [4][7]
Product description as published
Rhythm AI's website describes STAR Apollo as giving electrophysiologists a patient-specific map by identifying sources of activation based on activation precedence, and states that the software is powered by deterministic AI algorithms rooted in first principles of electrophysiology, with proprietary algorithms identifying Repetitive Patterns of Activation. The same publisher describes purple arrows that summarize dominant activation direction and red spheres marking Early Sites of Activation where activity emanates in all directions. [2][3]
The indications language in the K253733 comparison describes the system as assisting users in the interpretation and manual annotation of 3D anatomical and electrical maps of human atria using data from multipolar, intracardiac, atrial electrograms. The 2022 determination letter carries comparable manual-annotation language for the same trade name. [4][7]
Compatibility and stated availability
Rhythm AI states that STAR Apollo is FDA cleared for use with the Abbott Ensite™ X EP System and the Johnson & Johnson CARTO™ 3 Mapping System, and that it is not commercially available outside the U.S. The company's product page describes compatibility with two commercially available 3D mapping systems, a live feed superimposing ESAs and RPAs onto geometry collected on an external mapping system in real time, and no additional consumables required. [2][3]
A January 21, 2026 company announcement describes FDA 510(k) clearance for a new STAR Apollo Mapping System that expands compatibility to include the CARTO™ 3 Mapping System, and states that US clinical evaluations of the new system were to be launched in early 2026. A September 24, 2024 announcement describes clearance of the commercial release version and completion of first-in-human cases at Baptist Health, Jacksonville, Florida. [5][8]
Identity and what the record does not establish
The FDA records identify Rhythm AI, Ltd. as the applicant, and the company's own pages use the Rhythm AI name and trademark notices for STAR Apollo. The public documents do not establish a parent company, ownership structure, headquarters, customer list or total portfolio; the London address appears in a filing, and filing addresses are not treated here as headquarters. [1][2][4]
The one linked record and its single SESE decision describe the supplied filings as of the snapshot date, not company sales, total portfolio size or safety performance. Clinical outcome figures reported in company announcements are outside the scope of this profile. [1][6]

